IRELAND – Medtronic has announced that the US FDA has approved its new recharge-free InterStim X designed with the most personalized options to fit patient lifestyles.

The latest sacral neuromodulation (SNM) therapy product from the InterStim portfolio is now available from the medtech giant.

InterStim Micro uses sacral neuromodulation (SNM) therapy to treat patients with overactive bladder, fecal incontinence, and non-obstructive urinary retention.

Unlike oral medications, which target the muscular component of bladder control, SNM provides symptom control through direct modulation of nerve activity, restoring normal communication between the bladder and the brain.

InterStim X uses proprietary fifth-generation battery chemistry to provide more than ten years of battery life without recharging, increasing patient freedom and decreasing maintenance.

The new InterStim X system provides 10 to 15yrs. of battery life without the need to recharge. The device is expected to be available shortly.

With a monthly recharge, InterStim Micro’s proprietary overdrive battery technology provides more than 15 years of battery life.

According to the company, it is the smallest and most powerful rechargeable SNM device on the market.

Both systems include a smart programmer that looks like a standard smartphone, allowing patients to adjust their choice of 11 therapy settings discreetly and independently at home or on the go.

Both devices also feature SureScan technology, which allows for full-body 1.5 Tesla and 3Tesla MRI scans under certain conditions and eliminates the need for impedance checks.

To improve bladder and bowel control, SNM sends electrical impulses to the sacral nerves located in the lower back.

Earlier on, the US FDA approved Medtronic’s Freezor and Freezor Xtra cardiac cryoablation focal catheters for the treatment of pediatric atrioventricular nodal reentrant tachycardia (AVNRT)

The approval was based on the (ICY-AVNRT) and multiple pediatric studies that demonstrated the safety and efficacy of Freezor and Freezor Xtra cardiac cryoablation catheters and reported an acute procedural success rate of 95% with no permanent pacemaker due to complete AV block, as well as high efficacy rates and low adverse events.

The freezor cryoablation catheters line also includes the freezor MAX cardiac cryoablation catheter, which is approved for use with the Arctic Front Advance cryoballoon for atrial fibrillation.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE